Analysts predict that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will report earnings of ($0.09) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics reported earnings of ($0.08) per share during the same quarter last year, which suggests a negative year over year growth rate of 12.5%. The firm is scheduled to report its next earnings report on Tuesday, November 6th.
On average, analysts expect that Pluristem Therapeutics will report full year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.36) to ($0.35). For the next financial year, analysts forecast that the business will post earnings of ($0.25) per share, with EPS estimates ranging from ($0.29) to ($0.20). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Pluristem Therapeutics.
Pluristem Therapeutics (NASDAQ:PSTI) last announced its quarterly earnings data on Thursday, September 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.09). The firm had revenue of $0.05 million during the quarter.
PSTI has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 12th. HC Wainwright restated a “buy” rating and issued a $3.50 price objective on shares of Pluristem Therapeutics in a report on Friday, September 28th. Finally, B. Riley initiated coverage on shares of Pluristem Therapeutics in a report on Tuesday, July 31st. They issued a “buy” rating and a $4.50 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $3.13.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. ARK Investment Management LLC grew its position in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 87.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,436,501 shares of the biotechnology company’s stock after purchasing an additional 669,077 shares during the quarter. ARK Investment Management LLC owned approximately 1.30% of Pluristem Therapeutics worth $1,753,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.57% of the company’s stock.
Shares of PSTI opened at $1.18 on Tuesday. Pluristem Therapeutics has a twelve month low of $1.06 and a twelve month high of $1.67. The firm has a market capitalization of $128.36 million, a PE ratio of -4.72 and a beta of 0.32.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
See Also: Day Trading – Risk Worth the Reward?
Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.